WuXi PharmaTech has extended its collaboration with AstraZeneca for an additional three years. The first collaboration between the two companies, a $14 million two-year agreement begun in 2006, was very successful. During the last two years, using its high throughput screening capability, WuXi delivered over 100,000 compounds to AstraZeneca, two months ahead of schedule. The new agreement calls for WuXi to, once again, synthesize compounds, following designs indicated by AstraZeneca. More details...

Stock Symbols: (NYSE: WX) (NYSE: AZN)